Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

Raymund R Razonable, A. Rivero, A. Rodriguez, J. Wilson, J. Daniels, G. Jenkins, T. Larson, W. C. Hellinger, J. R. Spivey, C. V. Paya

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

The natural history of cytomegalovirus (CMV) disease associated with solid organ transplantation has been modified as a result of the widespread use of antiviral prophylaxis. Anecdotal reports have indicated a reduction of CMV disease at the expense of its later occurrence after completion of ganciclovir prophylaxis. The present study investigated the occurrence of CMV disease and its risk factors among 37 liver and kidney transplant recipients with CMV D+/Rstatus who received oral ganciclovir during the first 100 days posttransplantation. CMV disease occurred in 9 patients (24.3%) at a median of 144 days posttransplantation (range, 95-190 days). Allograft rejection was found to be strongly associated with the occurrence of late-onset CMV disease (risk ratio, 6.6; 95% confidence interval, 1.4-32.1; P = .02). Thus, CMV D+/R- solid organ transplant recipients receiving 3 months of oral ganciclovir who develop allograft rejection during the period of antiviral prophylaxis may benefit from extended and/or enhanced antiviral prophylaxis to prevent late-onset CMV disease.

Original languageEnglish (US)
Pages (from-to)1461-1464
Number of pages4
JournalJournal of Infectious Diseases
Volume184
Issue number11
DOIs
StatePublished - Dec 1 2001
Externally publishedYes

Fingerprint

Ganciclovir
Cytomegalovirus
Allografts
Transplants
Antiviral Agents
Late Onset Disorders
Organ Transplantation
Natural History
Odds Ratio
Confidence Intervals
Kidney
Liver

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. / Razonable, Raymund R; Rivero, A.; Rodriguez, A.; Wilson, J.; Daniels, J.; Jenkins, G.; Larson, T.; Hellinger, W. C.; Spivey, J. R.; Paya, C. V.

In: Journal of Infectious Diseases, Vol. 184, No. 11, 01.12.2001, p. 1461-1464.

Research output: Contribution to journalArticle

Razonable, Raymund R ; Rivero, A. ; Rodriguez, A. ; Wilson, J. ; Daniels, J. ; Jenkins, G. ; Larson, T. ; Hellinger, W. C. ; Spivey, J. R. ; Paya, C. V. / Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. In: Journal of Infectious Diseases. 2001 ; Vol. 184, No. 11. pp. 1461-1464.
@article{7ea8fee9b8714f9a8409b5b2a7d7f479,
title = "Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir",
abstract = "The natural history of cytomegalovirus (CMV) disease associated with solid organ transplantation has been modified as a result of the widespread use of antiviral prophylaxis. Anecdotal reports have indicated a reduction of CMV disease at the expense of its later occurrence after completion of ganciclovir prophylaxis. The present study investigated the occurrence of CMV disease and its risk factors among 37 liver and kidney transplant recipients with CMV D+/Rstatus who received oral ganciclovir during the first 100 days posttransplantation. CMV disease occurred in 9 patients (24.3{\%}) at a median of 144 days posttransplantation (range, 95-190 days). Allograft rejection was found to be strongly associated with the occurrence of late-onset CMV disease (risk ratio, 6.6; 95{\%} confidence interval, 1.4-32.1; P = .02). Thus, CMV D+/R- solid organ transplant recipients receiving 3 months of oral ganciclovir who develop allograft rejection during the period of antiviral prophylaxis may benefit from extended and/or enhanced antiviral prophylaxis to prevent late-onset CMV disease.",
author = "Razonable, {Raymund R} and A. Rivero and A. Rodriguez and J. Wilson and J. Daniels and G. Jenkins and T. Larson and Hellinger, {W. C.} and Spivey, {J. R.} and Paya, {C. V.}",
year = "2001",
month = "12",
day = "1",
doi = "10.1086/324516",
language = "English (US)",
volume = "184",
pages = "1461--1464",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

AU - Razonable, Raymund R

AU - Rivero, A.

AU - Rodriguez, A.

AU - Wilson, J.

AU - Daniels, J.

AU - Jenkins, G.

AU - Larson, T.

AU - Hellinger, W. C.

AU - Spivey, J. R.

AU - Paya, C. V.

PY - 2001/12/1

Y1 - 2001/12/1

N2 - The natural history of cytomegalovirus (CMV) disease associated with solid organ transplantation has been modified as a result of the widespread use of antiviral prophylaxis. Anecdotal reports have indicated a reduction of CMV disease at the expense of its later occurrence after completion of ganciclovir prophylaxis. The present study investigated the occurrence of CMV disease and its risk factors among 37 liver and kidney transplant recipients with CMV D+/Rstatus who received oral ganciclovir during the first 100 days posttransplantation. CMV disease occurred in 9 patients (24.3%) at a median of 144 days posttransplantation (range, 95-190 days). Allograft rejection was found to be strongly associated with the occurrence of late-onset CMV disease (risk ratio, 6.6; 95% confidence interval, 1.4-32.1; P = .02). Thus, CMV D+/R- solid organ transplant recipients receiving 3 months of oral ganciclovir who develop allograft rejection during the period of antiviral prophylaxis may benefit from extended and/or enhanced antiviral prophylaxis to prevent late-onset CMV disease.

AB - The natural history of cytomegalovirus (CMV) disease associated with solid organ transplantation has been modified as a result of the widespread use of antiviral prophylaxis. Anecdotal reports have indicated a reduction of CMV disease at the expense of its later occurrence after completion of ganciclovir prophylaxis. The present study investigated the occurrence of CMV disease and its risk factors among 37 liver and kidney transplant recipients with CMV D+/Rstatus who received oral ganciclovir during the first 100 days posttransplantation. CMV disease occurred in 9 patients (24.3%) at a median of 144 days posttransplantation (range, 95-190 days). Allograft rejection was found to be strongly associated with the occurrence of late-onset CMV disease (risk ratio, 6.6; 95% confidence interval, 1.4-32.1; P = .02). Thus, CMV D+/R- solid organ transplant recipients receiving 3 months of oral ganciclovir who develop allograft rejection during the period of antiviral prophylaxis may benefit from extended and/or enhanced antiviral prophylaxis to prevent late-onset CMV disease.

UR - http://www.scopus.com/inward/record.url?scp=0035576910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035576910&partnerID=8YFLogxK

U2 - 10.1086/324516

DO - 10.1086/324516

M3 - Article

C2 - 11709790

AN - SCOPUS:0035576910

VL - 184

SP - 1461

EP - 1464

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 11

ER -